Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer [Exome-Seq]

ABSTRACT: Prostate cancer cells were cultured in the presence of the drug Zenith-3694 for a period of 16-20 weeks to develop drug-resistant cells and subjected to Exome sequencing.

ORGANISM(S): Homo sapiens

PROVIDER: GSE197772 | GEO | 2022/03/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer [RNA-Seq]

Project description:Prostate cancer cells were cultured in the presence of the drug Zenith-3694 for a period of 16-20 weeks to develop drug-resistant cells and subjected to RNA sequencing.

2022-03-05 | GSE197557 | GEO

AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-03-05 | GSE197773 | GEO

AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer [Exome-Seq]

Project description:AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer [Exome-Seq]

| PRJNA812027 | ENA

AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer

Project description:AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer

| PRJNA812021 | ENA

AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer [RNA-Seq]

Project description:AKT/ERK-mediated activation of CDK7-MED1-AR axis drives resistance to pan BET bromodomain inhibitor ZEN-3694 in advanced prostate cancer [RNA-Seq]

| PRJNA810969 | ENA

CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.

Project description: Not available

| S-EPMC7202356 | biostudies-literature

ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Project description: Not available

| S-EPMC5838364 | biostudies-literature

Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma.

Project description: Not available

| S-EPMC10212919 | biostudies-literature

CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation

Project description:We performed RNA-seq and ChIP-seq in three prostate cell lines (VCaP, LNCaP and DU145) to ascertain the role of the mediator complex MED1 in AR signaling. Upon androgen stimulation, MED1 undergoes phosphorylation by CDK7 and physically engages with AR at super-enhancer sites, which is essential for AR-mediated transcription. The CDK7 specific inhibitor THZ1 blunts AR-dependent neoplastic growth by preventing the co-recruitment of AR/MED1 in a genome-wide fashion, and reverts the enzalutamide resistance characterized by hyper-phosphorylated MED1. The effect of THZ1 phenocopies that for MED1 and CDK7 knockdown.

2019-08-20 | GSE125245 | GEO

Design, Synthesis, and Characterization of a Fluorescence Polarization Pan-BET Bromodomain Probe.

Project description: Not available

| S-EPMC6295860 | biostudies-literature